<DOC>
	<DOCNO>NCT01838694</DOCNO>
	<brief_summary>The primary objective study evaluate safety , tolerability , efficacy 4 week intravenous treatment Cpn10 subject mild moderate active SLE .</brief_summary>
	<brief_title>Double-Blinded , Randomized , Placebo-Controlled Study Investigate Safety , Tolerability , Pharmacokinetics , Biochemical Activity Intravenous Cpn10 Administration Subjects With Mild Moderate SLE .</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Early pregnancy factor</mesh_term>
	<criteria>Inclusion Criteria ( ALL must meet ) : To enter study , subject must meet following criterion : 1 . Male female 2 . Age 18 75 year 3 . Patients fulfil least 4 criterion SLE define American College Rheumatology ( ACR ) 4 . Laboratory value follow : Documented ANA titer ≥ 1:160 positive antidsDNA antibody , time prior screening ( verifiable laboratory result ) 5 . Not pregnant breastfeed 6 . If corticosteroid require disease stability prior study entry , able tolerate stable dose ≤ 0.3 mg/kg/day prednisone equivalent duration study . 7 . Agreement use effective form contraception duration study . 8 . Ability understand give consent . 9 . Willing participate able comply study requirement , procedure visit . Mild SLE 10 . Present mild active SLE disease Moderate SLE 11 . Present active SLE disease base SLE disease activity score ( SLEDAI ) ≥4 ≤10 12 . MCP1 urinary level &gt; 35 pg/ml 13 . IL6 serum level &gt; 10 pg/ml 14 . Meets American College Rheumatology ( ACR ) condition `` renal disorder '' one diagnostic criterion SLE i.e . 1 . Persistent proteinuria 0.5 1.0 gram per day &gt; 3+ dipstick OR 2 . Cellular castsmay red cell , hemoglobin , granular , tubular , mixed OR 15 . Physician ( Pathologist ) diagnosis lupus nephritis great severity : 1 . Class I Minimal mesangial lupus nephritis , OR 2 . Class II Mesangial proliferative lupus nephritis , accordance International Society Nephrology ( ISN ) Renal Pathology Society ( RPS ) 2003 histological classification . With diagnosis make ≥ 6 month prior study commencement . 16 . If inclusion criterion # 15 met , subject must receive stable Standard Care , include hydroxychloroquine , treatment appropriate class III nephritis . Exclusion Criteria ( NONE apply ) : 1 . Active severe SLE flare central nervous system ( CNS ) and/or renal manifestation , pericarditis , active pleuritis , active peritonitis SLE manifestation require treatment allow study protocol within 4 week screen 2 . Pregnant breastfeed 3 . Lack peripheral venous access . 4 . History cardiovascular disease . An acute cardiovascular event within 12 month study entry , include arterial venous thrombosis ( blood clot ) . 5 . Requirement stable dose corticosteroid &gt; 0.3 mg/kg/day prednisone equivalent . 6 . Active therapy human murine monoclonal antibody ( i.e . belimumab ) , within 2 month study entry . 7 . Any experimental therapy within 3 month study entry . 8 . Therapy cyclophosphamide p.o parenteral ; pulse methylprednisolone IVIG within 46 week . 9 . Subjects treat sulfonylurea . 10 . Subjects follow laboratory abnormality : serum creatinine &gt; 3.0 mg/dL , WBC &lt; 3,500/μL , ANC &lt; 3,000/μL , absolute lymphocyte count ≤500/μL , Hgb &lt; 8.0 g/dL , platelet &lt; 50,000/μL , ALT and/or AST &gt; 1.5 x upper limit normal ( ULN ) , alkaline phosphatase &gt; 1.5 ULN . 11 . Personal psychiatric condition precludes subject able comply study requirement understand agree informed consent process . 12 . Recent systemic bacterial , fungal , viral , parasitic infection . Have require management/treatment hospitalization infection within last 4 week screen . 13 . History malignancy except completely excise basal cell carcinoma . 14 . Impaired hepatic function 15 . Body weight 260lbs/120kg ( BMI &gt; 35 ) 16 . History tuberculosis ( TB ) active , continue treatment TB 17 . History current alcohol substance abuse Mild SLE 18 . Active lupus nephritis and/or severe renal impairment ( estimate measure GFR &lt; 50 % predict age gender ) Moderate SLE 19 . Subjects recently diagnose lupus nephritis ( diagnosis make &lt; 6 month prior commencement study 20 . Subjects active urinary sediment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>